Akebia Therapeutics(AKBA) ZACKS·2025-05-01 15:07Core Viewpoint - Akebia Therapeutics (AKBA) is anticipated to report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended March 2025, with a consensus outlook suggesting a quarterly loss of 45.21 million, a 38.6% increase from the same quarter last year [1][3]. Earnings Expectations - The stock price may rise if the actual earnings exceed expectations in the upcoming report, while a miss could lead to a decline in stock value [2]. - The consensus EPS estimate has been revised 30% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates a positive Earnings ESP of +45.46% for Akebia Therapeutics, suggesting a strong likelihood of beating the consensus EPS estimate [11]. - The company currently holds a Zacks Rank of 3, which, when combined with the positive Earnings ESP, indicates a favorable outlook for the upcoming earnings report [11]. Historical Performance - In the last reported quarter, Akebia Therapeutics was expected to post a loss of 0.10, resulting in a surprise of -25% [12]. - Over the past four quarters, the company has only surpassed consensus EPS estimates once [13]. Industry Comparison - Another player in the Zacks Medical - Drugs industry, Heron Therapeutics (HRTX), is expected to report a loss of 37.08 million, a 7% increase from the previous year [17]. - Heron Therapeutics has seen a 50% upward revision in its consensus EPS estimate over the last 30 days and holds an Earnings ESP of 100.00%, indicating a strong likelihood of beating the consensus EPS estimate [18].